London
· Delayed Price · Currency is GBP · Price in CHF Kuros Biosciences AG Statistics
Total Valuation
Kuros Biosciences AG has a market cap or net worth of GBP 729.81 million. The enterprise value is 718.79 million.
| Market Cap | 729.81M |
| Enterprise Value | 718.79M |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -17.17% |
| Shares Change (QoQ) | -43.09% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 25.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 43.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -91.86 |
| EV / Sales | 15.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -251.40 |
Financial Position
The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.73 |
| Quick Ratio | 2.08 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.60 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -14.32% and return on invested capital (ROIC) is -4.54%.
| Return on Equity (ROE) | -14.32% |
| Return on Assets (ROA) | -3.77% |
| Return on Capital (ROIC) | -4.54% |
| Revenue Per Employee | 436,475 |
| Profits Per Employee | -73,817 |
| Employee Count | 80 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 1.14 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +432.69% in the last 52 weeks. The beta is 0.92, so Kuros Biosciences AG's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | +432.69% |
| 50-Day Moving Average | 22.95 |
| 200-Day Moving Average | 15.93 |
| Relative Strength Index (RSI) | 48.31 |
| Average Volume (20 Days) | 6,354 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kuros Biosciences AG had revenue of GBP 46.27 million and -7.82 million in losses. Loss per share was -0.27.
| Revenue | 46.27M |
| Gross Profit | 40.61M |
| Operating Income | -4.13M |
| Pretax Income | -6.49M |
| Net Income | -7.82M |
| EBITDA | -2.69M |
| EBIT | -4.13M |
| Loss Per Share | -0.27 |
Balance Sheet
The company has 12.57 million in cash and 1.73 million in debt, giving a net cash position of 10.84 million.
| Cash & Cash Equivalents | 12.57M |
| Total Debt | 1.73M |
| Net Cash | 10.84M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 52.99M |
| Book Value Per Share | 2.51 |
| Working Capital | 18.56M |
Cash Flow
In the last 12 months, operating cash flow was -2.13 million and capital expenditures -732,625, giving a free cash flow of -2.86 million.
| Operating Cash Flow | -2.13M |
| Capital Expenditures | -732,625 |
| Free Cash Flow | -2.86M |
| FCF Per Share | n/a |
Margins
Gross margin is 87.77%, with operating and profit margins of -8.92% and -16.91%.
| Gross Margin | 87.77% |
| Operating Margin | -8.92% |
| Pretax Margin | -14.03% |
| Profit Margin | -16.91% |
| EBITDA Margin | -5.80% |
| EBIT Margin | -8.92% |
| FCF Margin | n/a |
Dividends & Yields
Kuros Biosciences AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 17.17% |
| Shareholder Yield | 17.17% |
| Earnings Yield | -1.07% |
| FCF Yield | -0.39% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kuros Biosciences AG has an Altman Z-Score of 6.08.
| Altman Z-Score | 6.08 |
| Piotroski F-Score | n/a |